These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 7214822)
1. Dacarbazine (DTIC) in malignant melanoma: reduced toxicity with protection from light. Koriech OM; Shükla VS Clin Radiol; 1981 Jan; 32(1):53-5. PubMed ID: 7214822 [TBL] [Abstract][Full Text] [Related]
2. Results of a randomized study comparing DTIC with TIC mustard in malignant melanoma. Costanza ME; Nathanson L; Costello WG; Wolter J; Brunk SF; Colsky J; Hall T; Oberfield RA; Regelson W Cancer; 1976 Apr; 37(4):1654-9. PubMed ID: 769936 [TBL] [Abstract][Full Text] [Related]
3. [Hypersensitivity to dacarbazine in patients with metastatic malignant melanoma]. Levy A; Guitera P; Kerob D; Ollivaud L; Archimbaud A; Dubertret L; Basset-Seguin N Ann Dermatol Venereol; 2006 Feb; 133(2):157-60. PubMed ID: 16508601 [TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in advanced metastatic and recurrent melanoma treated with DTIC. Pawlicki M; Skołyszewski J; Stryjewska B; Nosek H Tumori; 1987 Feb; 73(1):49-50. PubMed ID: 3824531 [TBL] [Abstract][Full Text] [Related]
5. Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma. Treudler R; Georgieva J; Geilen CC; Orfanos CE J Am Acad Dermatol; 2004 May; 50(5):783-5. PubMed ID: 15097966 [TBL] [Abstract][Full Text] [Related]
6. Letter: Disseminated intravascular coagulation syndrome with metastatic melanoma: Remission after treatment with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC). Susens GP; Hendrickson C; Barto DA; Sams BJ Ann Intern Med; 1976 Feb; 84(2):175-6. PubMed ID: 1252046 [No Abstract] [Full Text] [Related]
7. Comparative study of methyl-CCNU (NSC-95441) with cyclophosphamide (NSC-26271) and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) with vincristine (NSC-67574) in patients with disseminated malignant melanoma. Ahmann DL; Hahn RG; Bisel HF; Eagan RT; Edmonson JH Cancer Chemother Rep; 1975; 59(2 Pt 1):451-3. PubMed ID: 1097102 [No Abstract] [Full Text] [Related]
8. DTIC therapy in metastatic malignant melanoma: a simplified dose schedule. Pritchard KI; Quirt IC; Cowan DH; Osoba D; Kutas GJ Cancer Treat Rep; 1980; 64(10-11):1123-6. PubMed ID: 7459898 [TBL] [Abstract][Full Text] [Related]
9. [Dimethyl-triazeno-imidazol-carboxamide (DTIC)--a new cytostatic agent]. Klepp O Tidsskr Nor Laegeforen; 1975 Sep; 95(27):1550-1. PubMed ID: 1179374 [No Abstract] [Full Text] [Related]
10. [Photosensitization with DTIC therapy in metastatic malignant melanoma]. Bolling R; Meyer-Hamme S; Schauder S Hautarzt; 1980 Nov; 31(11):602-5. PubMed ID: 7451142 [TBL] [Abstract][Full Text] [Related]
11. 5-(3,3-Dimethyle-1-Triazeno) Imidazole-4-Carboxamide and Interleukin-2 Adjuvant Therapy in Resected High-Risk Primary and Regionally Metastatic Melanoma. Gill A; Gosain R; Gragg H; Bycroft R; Rai SN; Pan J; Chesney JA; Miller DM Am J Med Sci; 2019 Jan; 357(1):43-48. PubMed ID: 30611319 [TBL] [Abstract][Full Text] [Related]
12. Dacarbazine combined targeted therapy versus dacarbazine alone in patients with malignant melanoma: a meta-analysis. Jiang G; Li RH; Sun C; Liu YQ; Zheng JN PLoS One; 2014; 9(12):e111920. PubMed ID: 25502446 [TBL] [Abstract][Full Text] [Related]
13. Cyclophosphamide plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) with or without Corynebacterium parvum in metastatic malignant melanoma. Presant CA; Bartolucci AA; Smalley RV; Vogler WR Cancer; 1979 Sep; 44(3):899-905. PubMed ID: 383276 [TBL] [Abstract][Full Text] [Related]
14. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614 [TBL] [Abstract][Full Text] [Related]
15. Antimetastatic action and hematological toxicity of p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide used as prophylactic adjuvants to surgical tumor removal in mice bearing B16 melanoma. Sava G; Giraldi T; Lassiani L; Nisi C Cancer Res; 1984 Jan; 44(1):64-8. PubMed ID: 6690062 [TBL] [Abstract][Full Text] [Related]
16. Chemotherapy of disseminated malignant melanoma with imidazol carboxamide (DTIC) and cyclophosphamide. Preliminary results. Rudolf Z; Plesnicar S Anticancer Res; 1982; 2(1-2):37-9. PubMed ID: 7051959 [TBL] [Abstract][Full Text] [Related]
18. Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients. Chabot GG; Flaherty LE; Valdivieso M; Baker LH Cancer Chemother Pharmacol; 1990; 27(2):157-60. PubMed ID: 2249333 [TBL] [Abstract][Full Text] [Related]
19. Pilot study of preoperative chemotherapy with cisplatin, vinblastine, and dacarbazine in patients with local-regional recurrence of melanoma. Buzaid A; Legha SS; Balch CM; Ross M; Ring S; Plager C; Papadopoulos NE; el-Naggar AK; Benjamin RS Cancer; 1994 Nov; 74(9):2476-82. PubMed ID: 7923003 [TBL] [Abstract][Full Text] [Related]
20. Effects of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide and its metabolites on Novikoff hepatoma cells. Beal DD; Skibba JL; Whitnable KK; Bryan GT Cancer Res; 1976 Aug; 36(8):2827-31. PubMed ID: 179708 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]